<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03422263</url>
  </required_header>
  <id_info>
    <org_study_id>Bernerklinik</org_study_id>
    <nct_id>NCT03422263</nct_id>
  </id_info>
  <brief_title>Performance Under SGLT-2-Inhibitors in Humans</brief_title>
  <acronym>PUSH</acronym>
  <official_title>Early Performance in Patients With Type-II-Diabetes Mellitus Under New Treatment With SGLT-2-Inhibitors Compared to Control Groups.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Berner Klinik Montana</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Berner Klinik Montana</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The PUSH Study is conceived to investigate the early effects of SGLT-2-Inhibitors on the
      physical performance of patients with Type-II-Diabetes mellitus compared to patients under
      other therapy regimes. Patients shall be divided into 3 groups: I - Patients with type II
      diabetes mellitus under new treatment with an SGLT2-Inhibitor. II - Patients with type II
      diabetes mellitus without SGLT-2- Inhibitor medication. III - Patients without type II
      diabetes mellitus but with similar comorbidities to the previous groups.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      SGLT-2-Inhibitors have been shown to improve cardiovascular outcomes in patients with type II
      diabetes mellitus. Present evidence shows this effect to be not directly related to better
      serum glucose levels because the effect was measurable within several days of initiation of
      the treatment.

      In a prospective single-centre double-blinded comparative observational study, other aspects
      of the effect of SGLT-2-Inhibitors shall be analyzed from patient registry, particularly the
      physical performance of patients under new treatment with SGLT-2-Inhibitors. Patient consent
      will be sort for the analysis of clinical data during the duration of stay.

      Patients included in the registry suitable for analysis shall be divided into 3 groups: I -
      Patients with type II diabetes mellitus under new treatment with an SGLT2-Inhibitor. II -
      Patients with type II diabetes mellitus without SGLT-2- Inhibitor medication. III - Patients
      without type II diabetes mellitus but with similar comorbidities to the previous groups.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Anticipated">July 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>28 Days</target_duration>
  <primary_outcome>
    <measure>Distance</measure>
    <time_frame>28 days</time_frame>
    <description>Change in distance covered in metres (m).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of perceived exertion</measure>
    <time_frame>28 days</time_frame>
    <description>Change in modified Borg Scale as subjective assessment of moderate intensity physical activity ( Range 0 - 10)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Saturation</measure>
    <time_frame>28 days</time_frame>
    <description>Change in saturation after exertion, expressed in %</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Heart rate after exertion</measure>
    <time_frame>28 days</time_frame>
    <description>Change in heart rate after exertion, expressed as bpm</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum oxygen uptake</measure>
    <time_frame>28 days</time_frame>
    <description>Change in predicted VO2 max using distance covered in 6 minute walk test as follows 4.948 0.023*Mean 6 MWD (meters)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Muscle anatomy</measure>
    <time_frame>28 days</time_frame>
    <description>Change in muscle architecture parameter (MAP) measured as the mid-thigh diameter of the medial vastus muscle using B-mode sonography in centim√®tres (cm).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle physiology</measure>
    <time_frame>28 days</time_frame>
    <description>Muscle strength measured as hand grip in Newton using a hand dynamometer in kg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical</measure>
    <time_frame>28 days</time_frame>
    <description>change in routine laboratory parameter related to muscle status using measurements of creatinine kinase in serum, CK in U/l</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective Assessment</measure>
    <time_frame>28 days</time_frame>
    <description>Change in fatigue using a Fatigue Score questionnaire (FSMC) as assessed by patient (Range 20 - 100).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiographic parameters (function)</measure>
    <time_frame>28 days</time_frame>
    <description>Change in left ventricular function using doppler readings of LVOT: LVEF using Dusmenil Formula SV/LVEDV expressed in %.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle anatomy (echogenicity)</measure>
    <time_frame>28 days</time_frame>
    <description>Change in muscle architecture parameter (MAP) measured as the mid-thigh echogenicity of the lateral vastus muscle, using image J software, arbitary units (AU)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical (metabolic function)</measure>
    <time_frame>28 days</time_frame>
    <description>change in routine laboratory parameter related to metabolic function: Uric acid in serum, expressed in micromol/l</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body constitution (BMI)</measure>
    <time_frame>28 days</time_frame>
    <description>change in body mass index measured as weight/height x height expressed in kg/m2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body constitution (Hip circumference)</measure>
    <time_frame>28 days</time_frame>
    <description>change in hip circumference measured at the maximum posterior protrusion of the buttocks in cm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body constitution (Muscle mass predicted I)</measure>
    <time_frame>28 days</time_frame>
    <description>change in muscle mass predicted using the Baumgartner equation 0.2487(BM) + 0.0483(ST)-0.1584(GQUAD) +0.0732(HGS) +2.5843(SEX) + 5.8828 in kg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body constitution (Muscle mass predicted II)</measure>
    <time_frame>28 days</time_frame>
    <description>change in muscle mass predicted using the muscle thickness of the forearm (4.89xMT-Ulna(cm)xHeight(m)-9.15) in kg</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Echocardiographic parameters (GLS)</measure>
    <time_frame>28 days</time_frame>
    <description>Change in left ventricular systolic function using global longitudinal strain Imaging: GLS expressed as GLS avg in minus %.</description>
  </other_outcome>
  <other_outcome>
    <measure>Biochemical (NTproBNP)</measure>
    <time_frame>28 days</time_frame>
    <description>change in routine laboratory parameter related to cardiac function using measurements of NTproBNP in ng/l</description>
  </other_outcome>
  <other_outcome>
    <measure>Echocardiographic parameters (LVEDV)</measure>
    <time_frame>28 days</time_frame>
    <description>Change in left ventricular structure using B-mode Imaging: LVEDV in mm</description>
  </other_outcome>
  <other_outcome>
    <measure>Echocardiographic parameters (LAVI)</measure>
    <time_frame>28 days</time_frame>
    <description>Change in left atrial structure structure using Biplane method: LAVI in ml/m2</description>
  </other_outcome>
  <other_outcome>
    <measure>Echocardiographic parameters (LV Massindex)</measure>
    <time_frame>28 days</time_frame>
    <description>Change in left ventricular structure using B-mode Imaging: LV Massindex in g/m2</description>
  </other_outcome>
  <other_outcome>
    <measure>Echocardiographic parameters (E/e' avg)</measure>
    <time_frame>28 days</time_frame>
    <description>Change in left ventricular diastolic function using Mitral inflow E velocity as obtained by pulsed-wave (PW) Doppler expressed E/e' avg ratio</description>
  </other_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Patients with T2DM under new therapy with SGLT-2-Inhibitors</arm_group_label>
    <description>Patients with T2DM under new therapy with SGLT-2-Inhibitors (Empagliflozin 10 mg per day, Dapagliflozin 10 mg per day, Canagliflozin 100 mg per day) at baseline.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with T2DM without SGLT-2-Inhibitors.</arm_group_label>
    <description>Patients with T2DM without therapy with SGLT-2-Inhibitors (Empagliflozin 10 mg per day, Dapagliflozin 10 mg per day, Canagliflozin 100 mg per day) at baseline.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients without T2DM manifesting similar comorbidities</arm_group_label>
    <description>Patients without T2DM manifesting similar comorbidities (Haemoglobin value, renal function, similar body mass index, cardiovascular disease profile)</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Ambulatory patients above the age of 40 who provide informed consent.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  informed consent

          -  ambulatory patients

        Exclusion Criteria:

          -  relevant limitations in movement
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Devine S Frundi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Berner Klinik Montana</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Devine S Frundi, MD</last_name>
    <phone>+41 27 485 5277</phone>
    <email>devine.frundi@bernerklinik.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>Berner Klinik Montana</name>
      <address>
        <city>Crans-Montana</city>
        <state>Valais</state>
        <zip>3963</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Devine S Frundi, MD</last_name>
      <phone>+41 274855242</phone>
      <email>devine.frundi@bernerklinik.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>January 23, 2018</study_first_submitted>
  <study_first_submitted_qc>January 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2018</study_first_posted>
  <last_update_submitted>July 7, 2020</last_update_submitted>
  <last_update_submitted_qc>July 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Berner Klinik Montana</investigator_affiliation>
    <investigator_full_name>Devine Frundi</investigator_full_name>
    <investigator_title>Lead physician of internal medicine (Leitender Arzt Medizin)</investigator_title>
  </responsible_party>
  <keyword>SGLT-2-Inhibitor, Empagliflozin, Canagliflozin, Dapagliflozin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Results of the study for academic purposes for trainees to get an academic degree within Switzerland.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

